Cardiovascular risk factors and carotid intima-media thickness with neurocognitive dysfunction in people living with HIV on stable combination anti-retroviral therapy
-
Published:2024-02-15
Issue:3
Volume:14
Page:
-
ISSN:2190-572X
-
Container-title:3 Biotech
-
language:en
-
Short-container-title:3 Biotech
Author:
Nayak Unnathi, Dsouza Nikhil Victor, Rai P. V. Santosh, Achappa BasavaprabhuORCID, Holla Ramesh, Murlimanju B. V.
Abstract
AbstractThe goal of this clinical research was to determine the relationship between carotid intima-media thickness (cIMT), cardiovascular risk factors, and neuro-cognitive function in people living with HIV (PLHIV) and were on stable combination anti-retroviral therapy (cART). This is a cross-sectional study performed at a single center, including 149 patients who visited the anti-retroviral therapy center of our tertiary care hospital. Among the PLHIV of our research, 62.4% had at least one associated cardiovascular risk factor, and 61.1% of them had abnormally high cIMT (≥ 0.9 mm on any one side, p = 0.035). These factors and being the male gender (p = 0.028) were associated with a greater Framingham 10-year risk percentage. Hypercholesterolemia was observed in 30.9% of the PLHIV and a higher body mass index (≥ 25 kg/m2) was found in 26.8% of them. The cognitive impairment was milder in 71.8% of cases and moderate in 9.4% of PLHIV. The Chi-square test revealed that a higher proportion of participants who had lower HDL-C levels (p = 0.045), smokers (p = 0.029), systolic blood pressure ≥ 140 mmHg (p = 0.012), and lower educational status (p = 0.017) had a poorer cognitive performance. In our sample population, a higher prevalence of elevated cIMT, cardiovascular risk factors, and mild and moderate cognitive deficiency was observed in PLHIV, who were on stable cART. However, routine assessment of the neuropsychological functions and management of modifiable risk factors are not performed in our patients. Further exploration of the relationship between cardiovascular risks, cIMT, and cognitive impairment in PLHIV is essential to formulate the guidelines and delay the onset of neurocognitive disorders in these patients.
Funder
Indian Council of Medical Research
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Ances BM, Sisti D, Vaida F, Liang CL, Leontiev O, Perthen JE, Buxton RB, Benson D, Smith DM, Little SJ, Richman DD, Moore DJ, Ellis RJ, HNRC group (2009) Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology 73(9):702–708 2. Bijker R, Jiamsakul A, Uy E, Kumarasamy N, Ditango R, Chaiwarith R, Wong WW, Avihingsanon A, Sun LP, Yunihastuti E, Pujari S, Do CD, Merati TP, Kantipong P, Nguyen KV, Kamarulzaman A, Zhang F, Lee MP, Choi JY, Tanuma J, Ng OT, Sim B, Ross J, Kiertiburanakul S, TREAT Asia HIV Observational Database (TAHOD) of IeDEA Asia-Pacific (2019) Cardiovascular disease-related mortality and factors associated with cardiovascular events in the TREAT Asia HIV Observational Database (TAHOD). HIV Med 20(3):183–191 3. Calza L, Manfredi R, Colangeli V, Trapani FF, Salvadori C, Magistrelli E, Danese I, Verucchi G, Serra C, Viale P (2013) Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active anti-retroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Res Hum Retrovir 29(3):547–556 4. Ciccarelli N, Grima P, Fabbiani M, Baldonero E, Borghetti A, Milanini B, Limiti S, Colafigli M, Tamburrini E, Cauda R, De Luca A, Di Giambenedetto S (2015) Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients. Antivir Ther 20(4):433–440 5. Cook R, Jones DL, Nehra R, Kumar AM, Prabhakar S, Waldrop-Valverde D, Sharma S, Kumar M (2016) HIV Clade-C infection and cognitive impairment, fatigue, depression, and quality of life in early-stage infection in northern Indians. J Int Assoc Provid AIDS Care 15(4):332–337
|
|